Broad Protection of Pigs Against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic RVaccinia (VACV) Vaccine Boost

Overview

Journal Vaccines (Basel)

Date 2020 Mar 4

PMID 32121277

Citations 10

Authors

Junru Cui

Caitlin M OConnell

Connor Hagen

Kim Sawicki

Joan A Smyth

Paulo H Verardi

Herbert J Van Kruiningen

Antonio E Garmendia

Affiliations

Soon will be listed here.

Abstract

Background: Porcine reproductive and respiratory syndrome (PRRS) viruses are a major cause of disease and economic loss in pigs worldwide. High genetic diversity among PRRSV strains is problematic for successful disease control by vaccination. Mosaic DNA and vaccinia (VACV) vaccines were developed in order to improve protection against heterologous PRRSV strains.

Methods: Piglets were primed and boosted with GP5-Mosaic DNA vaccine and recombinant GP5-Mosaic VACV (rGP5-Mosaic VACV), respectively. Pigs vaccinated with rGP5-WT (VR2332) DNA and rGP5-WT VACV, or empty vector DNA and empty VACV respectively, served as controls. Virus challenge was given to separate groups of vaccinated pigs with VR2332 or MN184C. Necropsies were performed 14 days after challenge.

Results: Vaccination with the GP5-Mosaic-based vaccines resulted in cellular reactivity and higher levels of neutralizing antibodies to both VR2332 and MN184C PRRSV strains. In contrast, vaccination of animals with the GP5-WT vaccines induced responses only to VR2332. Furthermore, vaccination with the GP5-Mosaic based vaccines resulted in protection against challenge with two heterologous virus strains, as demonstrated by the significantly lower viral loads in serum, tissues, porcine alveolar macrophages (PAMs), and bronchoalveolar lavage (BAL) fluids, and less severe lung lesions after challenge with either MN184C or VR2332, which have only 85% identity. In contrast, significant protection by the GP5-WT based vaccines was only achieved against the VR2332 strain. Conclusions GP5-Mosaic vaccines, using a DNA-prime/VACV boost regimen, conferred protection in pigs against heterologous viruses.

Citing Articles

Current Status of Porcine Reproductive and Respiratory Syndrome Vaccines.

Wang H, Feng W Vaccines (Basel). 2025; 12(12.

PMID: 39772049 PMC: 11679953. DOI: 10.3390/vaccines12121387.

Research Progress on the Development of Porcine Reproductive and Respiratory Syndrome Vaccines.

Zhang H, Luo Q, He Y, Zheng Y, Sha H, Li G Vet Sci. 2023; 10(8).

PMID: 37624278 PMC: 10459618. DOI: 10.3390/vetsci10080491.

Production of a chimeric porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine using a lab-scale packed-bed bioreactor CelCradle.

Choi H, Choi J, Kang Y, Ahn S, Lee S, Park S BMC Vet Res. 2023; 19(1):105.

PMID: 37528389 PMC: 10394776. DOI: 10.1186/s12917-023-03659-4.

Testable Candidate Immune Correlates of Protection for Porcine Reproductive and Respiratory Syndrome Virus Vaccination.

Kick A, Grete A, Crisci E, Almond G, Kaser T Vaccines (Basel). 2023; 11(3).

PMID: 36992179 PMC: 10059210. DOI: 10.3390/vaccines11030594.

Research Progress on Glycoprotein 5 of Porcine Reproductive and Respiratory Syndrome Virus.

Luo Q, Zheng Y, Zhang H, Yang Z, Sha H, Kong W Animals (Basel). 2023; 13(5).

PMID: 36899670 PMC: 10000246. DOI: 10.3390/ani13050813.

References

Brown E, Lawson S, Welbon C, Gnanandarajah J, Li J, Murtaugh M . Antibody response to porcine reproductive and respiratory syndrome virus (PRRSV) nonstructural proteins and implications for diagnostic detection and differentiation of PRRSV types I and II. Clin Vaccine Immunol. 2009; 16(5):628-35. PMC: 2681581. DOI: 10.1128/CVI.00483-08. View

Ni Y, Opriessnig T, Zhou L, Cao D, Huang Y, Halbur P . Attenuation of porcine reproductive and respiratory syndrome virus by molecular breeding of virus envelope genes from genetically divergent strains. J Virol. 2012; 87(1):304-13. PMC: 3536372. DOI: 10.1128/JVI.01789-12. View

Kim H, Kwang J, Yoon I, Joo H, Frey M . Enhanced replication of porcine reproductive and respiratory syndrome (PRRS) virus in a homogeneous subpopulation of MA-104 cell line. Arch Virol. 1993; 133(3-4):477-83. DOI: 10.1007/BF01313785. View

Nelsen C, Murtaugh M, Faaberg K . Porcine reproductive and respiratory syndrome virus comparison: divergent evolution on two continents. J Virol. 1998; 73(1):270-80. PMC: 103831. DOI: 10.1128/JVI.73.1.270-280.1999. View

Santra S, Liao H, Zhang R, Muldoon M, Watson S, Fischer W . Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med. 2010; 16(3):324-8. PMC: 2834806. DOI: 10.1038/nm.2108. View

Geldhof M, Vanhee M, Van Breedam W, Van Doorsselaere J, Karniychuk U, Nauwynck H . Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges. BMC Vet Res. 2012; 8:182. PMC: 3514241. DOI: 10.1186/1746-6148-8-182. View

Morgan S, Graham S, Salguero F, Sanchez Cordon P, Mokhtar H, Rebel J . Increased pathogenicity of European porcine reproductive and respiratory syndrome virus is associated with enhanced adaptive responses and viral clearance. Vet Microbiol. 2013; 163(1-2):13-22. DOI: 10.1016/j.vetmic.2012.11.024. View

Deng Y, Chuai X, Chen P, Chen H, Wang W, Ruan L . Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques. Vaccine. 2017; 35(25):3347-3353. DOI: 10.1016/j.vaccine.2017.04.059. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

10.

Tahoun A, Jensen K, Corripio-Miyar Y, McAteer S, Corbishley A, Mahajan A . Functional analysis of bovine TLR5 and association with IgA responses of cattle following systemic immunisation with H7 flagella. Vet Res. 2015; 46:9. PMC: 4333180. DOI: 10.1186/s13567-014-0135-2. View

11.

Hagen C, Titong A, Sarnoski E, Verardi P . Antibiotic-dependent expression of early transcription factor subunits leads to stringent control of vaccinia virus replication. Virus Res. 2014; 181:43-52. DOI: 10.1016/j.virusres.2013.12.033. View

12.

Kim T, Park C, Choi K, Jeong J, Kang I, Park S . Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs. Clin Vaccine Immunol. 2015; 22(6):631-40. PMC: 4446407. DOI: 10.1128/CVI.00001-15. View

13.

Bernelin-Cottet C, Urien C, Fretaud M, Langevin C, Trus I, Jouneau L . A DNA Prime Immuno-Potentiates a Modified Live Vaccine against the Porcine Reproductive and Respiratory Syndrome Virus but Does Not Improve Heterologous Protection. Viruses. 2019; 11(6). PMC: 6631340. DOI: 10.3390/v11060576. View

14.

Lampe K, Gottstein B, Becker T, Stahl-Hennig C, Kaup F, Matz-Rensing K . Immunization of rhesus macaques with Echinococcus multilocularis recombinant 14-3-3 antigen leads to specific antibody response. Parasitol Res. 2016; 116(1):435-439. PMC: 5167771. DOI: 10.1007/s00436-016-5303-z. View

15.

Wensvoort G, Terpstra C, Pol J, ter Laak E, Bloemraad M, de Kluyver E . Mystery swine disease in The Netherlands: the isolation of Lelystad virus. Vet Q. 1991; 13(3):121-30. DOI: 10.1080/01652176.1991.9694296. View

16.

Zuckermann F, Garcia E, Luque I, Christopher-Hennings J, Doster A, Brito M . Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge. Vet Microbiol. 2007; 123(1-3):69-85. DOI: 10.1016/j.vetmic.2007.02.009. View

17.

Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M . Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018; 392(10143):232-243. PMC: 6192527. DOI: 10.1016/S0140-6736(18)31364-3. View

18.

Han K, Seo H, Park C, Chae C . Vaccination of sows against type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) before artificial insemination protects against type 2 PRRSV challenge but does not protect against type 1 PRRSV challenge in late gestation. Vet Res. 2014; 45:12. PMC: 3923437. DOI: 10.1186/1297-9716-45-12. View

19.

Labarque G, Van Reeth K, Nauwynck H, Drexler C, Van Gucht S, Pensaert M . Impact of genetic diversity of European-type porcine reproductive and respiratory syndrome virus strains on vaccine efficacy. Vaccine. 2004; 22(31-32):4183-90. DOI: 10.1016/j.vaccine.2004.05.008. View

20.

Zhou L, Ni Y, Pineyro P, Sanford B, Cossaboom C, Dryman B . DNA shuffling of the GP3 genes of porcine reproductive and respiratory syndrome virus (PRRSV) produces a chimeric virus with an improved cross-neutralizing ability against a heterologous PRRSV strain. Virology. 2012; 434(1):96-109. DOI: 10.1016/j.virol.2012.09.005. View